Haemonetics Q1 Beat and Raised FY27 Guidance Signal Plasma Recovery

What happened

Haemonetics reported fiscal 2027 first-quarter earnings and revenue that exceeded analyst expectations, driven by growth in the Plasma segment and stronger cash generation. The company raised its fiscal 2027 revenue guidance, reflecting increased confidence in its near-term trajectory. This follows a period of uncertainty tied to the CSL Plasma disposables transition, which had pressured Plasma revenues and led to a cautious outlook in prior analyses. The previous DeepValue report indicated that evidence of Plasma stabilization and sustained Hospital outperformance would improve the risk-reward profile. The latest results suggest that the Plasma trough has likely passed, and the company's strategic focus on higher-growth areas is beginning to yield tangible benefits.

Implication

If Plasma growth persists and Hospital momentum continues, Haemonetics may warrant a higher valuation multiple as the CSL transition fades and the company demonstrates improved revenue quality and cash generation.

Thesis delta

The prior neutral thesis was predicated on awaits for Plasma stabilization post-CSL transition. This earnings report indicates that stabilization is occurring, with Plasma returning to growth and the company raising guidance. The thesis shifts to a more positive stance, contingent on continued execution and avoidance of new headwinds.